{"entity":{"id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","aka":[],"tldr":"A phase 1/2 trial of TRI-611 in non-small-cell lung cancer and small-cell lung cancer, run by TRIANA Biomedicines, Inc., now recruiting.","summary":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC is a phase 1/2 interventional study registered as NCT07491497 by TRIANA Biomedicines, Inc., with 160 participants planned, started 2026-03-11 and due to reach its primary completion in 2029-05-31. Interventions recorded: TRI-611. Conditions listed: ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07491497","url":"https://clinicaltrials.gov/study/NCT07491497"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tri-611"],"companies":["triana-biomedicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07491497","phase":"1/2","setting":"A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC","sponsor":"TRIANA Biomedicines, Inc.","enrolled":160,"outcomes":[]},"route":"/trials/nct07491497/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"tri-611","kind":"drug","name":"TRI-611","route":"/drugs/tri-611/"}],"company":[{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/"}]}}